Mocetinostat is under clinical development by Mirati Therapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to GlobalData, Phase II drugs for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mocetinostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mocetinostat overview

Mocetinostat is under development for the treatment of non-small cell lung cancer (NSCLC), relapsed and refractory diffuse large B-cell lymphoma, follicular lymphoma and relapsed and refractory Hodgkin lymphoma. It is administered through the oral route. It acts by targeting HDAC (histone deacetylase) I and IV.

It was also under development for the treatment of refractory and recurrent rhabdomyosarcoma, pancreatic cancer, refractory chronic lymphocytic leukaemia (CLL), acute myelocytic leukaemia (AML), Burkitt's lymphoma, non-Hodgkin lymphoma, bladder cancer and myelodysplastic syndrome, metastatic leiomyosarcoma and urothelial carcinoma.

Mirati Therapeutics overview

Mirati Therapeutics is a clinical-stage oncology company that developing novel therapeutics to address the genetic and immunological promoters of cancer. The company product pipeline includes Adagrasib (MRTX849), an oral small molecule inhibitor of KRASG12C and MRTX1133, a potent small molecule inhibitor of the KRASG12D for the treatment of colorectal and pancreatic cancer. Mirati Therapeutics is also evaluating Sitravatinib, a multi kinase inhibitor against non-small cells lung cancer in non-smokers and MRTX1719 to treat MTAP deleted cancers. The company has partner with Zai Lab, Beigene, Sanofi, Boehringer, Novartis and Bristol Myers Squibb, among others. It operates in Canada, Netherlands and the US. Mirati Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of Mocetinostat’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.